drugset / Trial / NCT06667141
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Timeline
- Start
- 2024-10-08
- Primary completion
- 2026-08-12
- Completion
- 2026-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACR-2316 | Unknown | — | — |
Indications
No indication recorded.